Innovative Solutions for Heart Failure with Preserved Ejection Fraction (HFpEF)

Over 5.7 million people in the US and 20 million people worldwide suffer from heart failure. About half of these patients suffer from Heart Failure with Preserved Ejection Fraction (HFpEF), characterized by abnormal diastolic function, the phase of the cardiac cycle in which the heart fills with blood. Currently there is no effective treatment for HFpEF. CorAssist is developing the first device based treatment of HFpEF aimed at augmentation of the heart diastolic function.

CorAssist is committed to developing innovative therapeutic products for the treatment of HFpEF using a device-based approach. The CORolla® is the first device to directly improve cardiac diastolic function. Based on mechanical principles of energy transfer from systole to diastole, the CORolla® does not require any external power source for its operation. The device is implanted by minimal invasive procedure on a beating heart, a Trans Apical Approach similar to TAVI like procedures.

Breaking News – First Implantation at Rambam Medical Center!

Currently Recruiting Patients for the CORolla^® Clinical Trial:

RAMBAM Medical Center
For more information please contact Dr. Anastasia Weis
Email: a_weis@rambam.health.gov.il
Tel: +97247772048

CORolla^®

ImCardia^®

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 832168.